Study finds stable trends in ventilator-associated pneumonia rates

In a study published online by JAMA, Mark L. Metersky, M.D., of the UConn School of Medicine, Farmington, and colleagues analyzed trends in Medicare Patient Safety Monitoring System ventilator-associated pneumonia rates from 2005 through 2013.

Whether previously reported decreases in the rates of ventilator-associated pneumonia (VAP) were attributable to better care or stricter application of subjective surveillance criteria is unclear. The Medicare Patient Safety Monitoring System (MPSMS) has independently measured VAP rates since 2005, using a stable definition of VAP. This analysis included MPSMS VAP rates during calendar years 2005 through 2013 among Medicare patients 65 years and older with principal diagnoses of heart attack, heart failure, pneumonia (including a primary diagnosis of sepsis or respiratory failure and a secondary diagnosis of pneumonia), and selected major surgical procedures. The cohort was divided into 4 periods (2005-2006, 2007 and 2009, 2010-2011, and 2012-2013).

The VAP rate was studied among 1,856 patients. The researchers found that the MPSMS VAP rates were stable over time, with an observed rate of 10.8 percent during 2005-2006, 9.7 percent during 2012-2013, and an adjusted average annual change of 0.

"From 2005 through 2013, MPSMS VAP rates remained stable and substantial, affecting approximately 10 percent of ventilated patients. Persistently high VAP rates bolster concerns that most interventions purported to reduce VAP are supported by limited evidence," the authors write.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers decode MRSA biofilm structure to combat antibiotic resistance